In vitro biotransformation of the new antipsychotic agent, RWJ-46344 in rat hepatic S9 fraction: API-MS/MS/MS identification of metabolites

The in vitro biotransformation of the antipsychotic agent, RWJ-46344 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-46344 (∼37% of the sample) plus 12 metabolites were profiled, quantified, and tentatively identified on the basi...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical and biomedical analysis Vol. 24; no. 2; pp. 307 - 316
Main Authors Wu, Wu-Nan, McKown, Linda A, Moyer, Michael D, Reitz, Allen B
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 15.12.2000
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The in vitro biotransformation of the antipsychotic agent, RWJ-46344 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-46344 (∼37% of the sample) plus 12 metabolites were profiled, quantified, and tentatively identified on the basis of API (ionspray)-MS/MS/MS data. The proposed metabolic pathways for RWJ-46344 are proposed, and the six metabolic pathways are 1, O-dealkylation; 2, piperidinyl oxidation; 3, N-debenzylation; 4, phenyl hydroxylation; 5, dehydration; and 6, reduction. Pathways 1 to 3 formed O-desisopropyl RWJ-46344 (M3,∼13% of the sample) and its hydroxy-metabolite (M5,∼8%), hydroxy-piperidinyl RWJ-46344 (M1,∼5%) and a phenylpiperidinyl metabolite (M8,∼24%) as major and moderate metabolites. Eight minor metabolites (each <2%) were formed via a combination of six steps. RWJ-46344 is metabolized substantially by this rat hepatic system.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0731-7085
1873-264X
DOI:10.1016/S0731-7085(00)00421-0